Evidence map›Paper›PMID 40697273›Full record

ArticleFrontiers in neuroscience2025

Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab

Andreia Gomes-Duarte, Sofia Pascoal, Rob Haselberg, Marina Sogorb-Gonzalez, Sander van Deventer

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Andreia Gomes-DuarteVectorY Therapeutics, Matrix Innovation Center VI, Amsterdam, Netherlands.
Sofia Pascoal *VectorY Therapeutics, Matrix Innovation Center VI, Amsterdam, Netherlands.
Rob Haselberg *VectorY Therapeutics, Matrix Innovation Center VI, Amsterdam, Netherlands.
Marina Sogorb-GonzalezVectorY Therapeutics, Matrix Innovation Center VI, Amsterdam, Netherlands.
Sander van DeventerVectorY Therapeutics, Matrix Innovation Center VI, Amsterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive motor neuron degeneration. Mutations in the superoxide dismutase 1 (SOD1) gene account for a significant fraction of familial ALS (fALS) cases. Oxidative stress and oxidized phosphatidylcholines (PC-OxPL) contribute to neuroinflammation and neuronal damage, and to motor neuron degeneration in ALS. We previously demonstrated the therapeutic efficacy of an AAV-delivered anti-PC-OxPL single-chain variable fragment (PC-OxPL-VecTab

Indexed as

adeno-associated virusesamyotrophic lateral sclerosisgene therapyoxidized phosphatidylcholinessuperoxide dismutase 1

Identifiers

PMID40697273
PMCPMC12279709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.